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Vascular permeability factor/vascular endothelial growth factor (VPF/VEGF), one of the crucial pro-angiogenic factors,
functions as a potent inhibitor of endothelial cell (EC) apoptosis. Previous progress has been made towards delineating the
VPF/VEGF survival signaling downstream of the activation of VEGFR-2. Here, we seek to define the function of NRP-1 in VPF/
VEGF-induced survival signaling in EC and to elucidate the concomitant molecular signaling events that are pivotal for our
understanding of the signaling of VPF/VEGF. Utilizing two different in vitro cell culture systems and an in vivo zebrafish model,
we demonstrate that NRP-1 mediates VPF/VEGF-induced EC survival independent of VEGFR-2. Furthermore, we show here
a novel mechanism for NRP-1-specific control of the anti-apoptotic pathway in EC through involvement of the NRP-1-
interacting protein (NIP/GIPC) in the activation of PI-3K/Akt and subsequent inactivation of p53 pathways and FoxOs, as well as
activation of p21. This study, by elucidating the mechanisms that govern VPF/VEGF-induced EC survival signaling via NRP-1,
contributes to a better understanding of molecular mechanisms of cardiovascular development and disease and widens the
possibilities for better therapeutic targets.
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Survival. PLoS ONE 2(11): e1161. doi:10.1371/journal.pone.0001161
INTRODUCTION
Apoptosis of the endothelial cell (EC) has been suggested to play an
important role in a number of common and life-threatening vascular
diseases, such as atherosclerosis, hypertension, and restenosis [1–5].
EC apoptotic death-induced loss of EC number and EC dysfunction
may constitute an initial causative step in, and have a critical role in,
the progress of many vascular pathological situations by compro-
mising vascular wall permeability to cytokines, growth factors, lipids
and immune cells, increasing smooth muscle cell proliferation and
enhancing blood coagulation [6–8]. However, the cascade of
molecular events that precede these final outcomes is largely
unknown. The intracellular signaling that regulates the onset and
execution of apoptosis has only been partially elucidated [9,10].
One possible reason for EC apoptosis may be the inappropriate
function of growth factors and their receptors [11], which are
critically involved in controlling cellular differentiation, growth, and
function.Onefunctionallyrelevantvasculargrowth factorisvascular
permeability factor/vascular endothelial growth factor (VPF/
VEGF) [12,13] that has been cited as one of the most important
pro-angiogenic factors. Neuropilin-1 (NRP-1) was recently found to
be one of the VPF/VEGF receptors, which is expressed in EC and
functions as an isoform-specific receptor for VPF/VEGF [14,15].
Although the original evidence suggests that the function of NRP-1
in VPF/VEGF signaling in EC occurs via the formation of complexes
involving VEGFR-2 and NRP-1 [14,15], our findings and those of
others have identified that NRP-1 regulates EC migration and
adhesion to extracellular matrix proteins independently of VEGFR-2
[16,17]. Moreover, recentlypublished data by Pan etal.indicatedthat
NRP-1 is crucial to modulating EC motility, thus demonstrating that
it plays roles beyond acting as an enhancer of VEGFR2 signaling
[18]. These observations suggest the possibility that NRP-1 may
either interact with other signaling receptors or independently
promote cell signaling. The latter is supported by our further studies
in which we revealed that the C-terminal three amino acids of NRP-1
(SEA-COOH) can interact with neuropilin-1 interacting protein
(NIP, also called RGS-GAIP-interacting protein ,GIPC.), which
mediates EC migration and angiogenesis [19]. Nevertheless, the
molecular mechanisms of the downstream signaling of GIPC and its
related function towards NRP-1 are not well understood.
Earlyin1995,Alonetal.reportedthatVPF/VEGFcouldfunction
as a potent inhibitor of apoptosis of ECs comprising newly formed
retinal vessels in neonatal rats exposed to hypoxia [20]. Sub-
sequently, Jain etal. reported VPF/VEGF could protectECofnewly
formed immature tumor vessels [21]. Considerable progress has also
been made towards delineating the VPF/VEGF survival signaling
distal to the activation of VEGFR-2 [22–25]. However, a recent
study found that the embryonic stem cell death pathway is overruled
by a survival pathway during prolonged hypoxia (48 h) in a process
involving HIF-1a-dependentup-regulation of VPF/VEGFwhich, in
an autocrine action involving VEGFR-2 and NRP-1, protects
againstapoptosis [26].Barr and co-workers [27] showed that NRP-1
plays an essential role in autocrine antiapoptotic signaling by VPF/
VEGF in tumor cells and that an NRP-1-blockade with an anti-
NRP-1 peptide corresponding to exon 7 [28] of VEGF165 induces
tumor cell and EC apoptosis. However, a VEGFR-2-blockade only
induces EC apoptosis [27], which suggests that both VEGFR-2 and
NRP-1 play an important role in VPF/VEGF-mediated EC survival
signaling. It also suggests that they may function together as
a receptor complex. More interestingly, Bachelder’s study found that
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survival and chemotaxis in tumor cells lacking expression of
VEGFR-1 and VEGFR-2 [29,30]. To date, it is unknown whether
NRP-1 can mediate VPF/VEGF-induced survival in EC indepen-
dent of VEGFR-2 and the involved molecular signaling events.
By selectively activating NRP-1 in cell culture and by using
a reverse genetic strategy in a zebrafish model, we explored the
mechanisms that govern VPF/VEGF-induced EC survival
signaling via NRP-1. We show here a novel mechanism for
a VEGFR-2-independent, NRP-1-specific control of the anti-
apoptotic pathway in EC which most likely involves GIPC and
then is mediated by the activation, respectively, of PI3K/Akt, the
p53/caspases and FoxOs axis, and p21.
Results NRP-1 mediates VPF/VEGF-induced EC
survival independent of VEGFR-2, and its C-terminal
three amino acids are essential for this function
We first established a system to efficiently and reproducibly induce
apoptosis in porcine aortic endothelial cell (PAEC) and human
umbilical vein endothelial cell (HUVEC). Subconfluent cells were
serum-starved (0.1%FBS) for 24 hours. Using TUNEL and
Annexin V-FITC/PI apoptosis detection assays, we found that
serum-starved cells showed a much higher prevalence of apoptosis
and typical apoptotic nuclei (Figure S1, a, b) as compared to the
cells grown in full medium.
As VEGFR-1, VEGFR-2, and NRP-1 are all expressed on EC,
it is difficult to distinguish their biological functions and signaling
pathways induced in EC by VPF/VEGF individually. Therefore,
to elucidate the distinct roles of NRP-1, we first used PAEC that
express none of the VPF/VEGF receptors. Wild-type PAEC and
PAEC transfected with NRP-1 cDNA (PAEC/NRP-1) were
analyzed for their survival when treated with VPF/VEGF. As
shown in Supp. Fig. 1a, apoptotic cells of parental PAEC treated
with VPF/VEGF were observed by TUNEL assay. However,
VPF/VEGF induced a significant decrease in apoptosis in PAEC/
NRP-1 relative to parental PAE cells, about five-and six-fold less
than VPF/VEGF-stimulated parental PAEC or serum-starved
PAEC/NRP-1 (Figure 1a). The percentage of apoptotic cells,
which was determined using an Annexin V-FITC Apoptosis
Detection Kit (Roche, Nutley, N.J.) with flow cytometry,
demonstrated that the stimulation of PAEC/NRP-1 with VPF/
Figure 1. NRP-1 mediates VPF/VEGF-induced EC survival; the C-terminal three amino acids of NRP-1 are essential for this function. a.
Quantitative determination of apoptotic nuclei in PAEC (n=8). TUNEL assay was performed in apoptosis-induced PAEC and PAEC/NRP-1 with or with
out 10ng/ml VPF/VEGF stimulation for 48 hrs to assess whether NRP-1 mediates PAEC survival. b. FACS apoptosis analysis to determine the
percentage of apoptotic PAEC. c. Quantitative determination of apoptotic nuclei in HUVEC (n=8. n: The number of counted field. All are same in this
study). EGNP-1 mediates HUVEC survival; the C-terminal three amino acids of NRP-1 are essential for this function. TUNEL assay was performed in
apoptosis-induced HUVEC transfected with EGNP-1 or EGNP-1DSEA and stimulated with or without 10ng/ml EGF. d. FACS apoptosis analysis to
determine the percentage of apoptotic HUVEC. All the experiments at least were repeated three times and duplicated-wells were used for each
experiment. *p,0.001, **p,0.005, ***p,0.01, ****p,0.05 in a Student’s t test. e. NRP-1 mediates EC survival in zebrafish; the C-terminal three amino
acids (SEA-COOH) are essential for the function. Fluorescent image of embryos injected with indicated morpholinos and mRNA, then subjected to the
antibody stain with anti-GFP antibody and TUNEL assay to detect apoptosis. Insets show a magnification of apoptotic foci in the vessel. The arrows
indicate apoptotic EC. i. Control; ii. Mismatch MO (4.5 ng); iii. zNRP-1a/1b MOs (4.5 ng+4.5 ng); iv. zNRP-1a/1b MOs (4.5 ng+4.5 ng)+hNRP-1 mRNA
(0.3ng); v. zNRP-1a/1b MOs (4.5ng+4.5ng)+hNRP-1DSEA mRNA (0.3 ng). f. The dynamics of NRP-1-induced EC apoptosis in the zebrafish embryo.
Fluorescent images of different stage embryos injected with indicated morpholinos and subjected to the antibody stain and TUNEL assay to detect
apoptosis. Insets show a magnification of apoptotic foci in the vessel. The arrows indicate apoptotic EC. i. Control; ii. zNRP-1a/1b MOs (3.0 ng+3.0 ng).
doi:10.1371/journal.pone.0001161.g001
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necrotic/late-apoptotic cells which were about three–fold lower
than in VPF/VEGF-stimulated PAEC (Figure. 1b). This result is
consistent with our findings using the TUNEL assay.
Furthermore, we engineered a chimeric receptor, EGNP-1, by
replacing the extracellular domains of NRP-1 with the N-terminal
domain of the epidermal growth factor receptor (EGFR), and
another chimeric mutant receptor, EGNP-1?SEA (created by
deleting the C-terminal three amino acids of NRP-1 (SEA-COOH))
[16].These receptors were used to further elucidate the role of NRP-
1 in VPF/VEGF-induced EC survival and the importance of the C-
terminal three amino acids of NRP-1 (SEA-COOH). The
concomitant stimulation of serum-deprived EGNP-1-transduced
HUVEC with epidermal growth factor (EGF, 10 ng/ml) led to
a decrease in apoptosis more than five-fold compared to the non-
stimulated control and the LacZ-transduced HUVEC. However,
EGF stimulation in EGNP-1?SEA-transduced HUVEC did not
yield a significant difference in apoptosis when compared to the
controlandtotheLacZ-transducedHUVEC(FigureS1b,Figure1c).
Flow cytometry confirmed that EGF induced a significant decrease
of apoptotic cells in EGNP-1-transduced HUVEC, but not in
EGNP-1?SEA-transduced HUVEC, which, by contrast, showed
more necrotic/late-apoptotic cells (Figure 1d). From these data, we
concluded that NRP-1/EGNP-1 mediates ligand-induced EC
survival independent of VEGFR-2, and that its C-terminal three
amino acids (SEA-COOH) are essential for this function.
We employed a reverse genetic strategy to explore the function
of NRP-1 in EC survival in a zebrafish model. Previously, we
cloned zebrafish NRP-1 genes (zNRP-1a/1b) and analyzed their
expression patterns by in situ hybridization [19]. In the current
study, to examine functions of NRP–1 in zebrafish EC apoptosis,
morpholinos are injected into a Fli-GFP transgenic fish line
(TG(fli1:egfp)y1), where all of the ECs are labeled with GFP.
Because of the transparency of zebrafish embryos, ECs can be
observed in living embryos in fluorescent green. After that, the
embryos were subjected to the TUNEL assay to detect apoptosis.
The identity of the apoptotic cells is confirmed by using the red
channel where EC should be labeled by Fli-GFP signal. The
evaluation of apoptotic EC should consider the overlay of red
signal and Fli-GFP green signal, and only red signal in EC
location. As shown in Figure 1e and Figure S1, c, d, following
knockdown of zebrafish NRP-1 by co-injecting NRP-1a/-1b
splicing donor morpholinos (MO) into single-cell staged embryos,
we found elevated levels of EC apoptosis compared with non MO
injected or nucleotide exchange MO injection embryos. TUNEL-
positive cells showed orange masses and were either rounded or
shrunken (pycnotic). Furthermore, the specific EC apoptotic
phenotype was suppressed by coinjection of human NRP-1
mRNA (Figure 1e, Figure S1, c, d). The ectopic expression of
human NRP-1 in zebrafish efficiently blocked zebrafish NRP-1
knockdown-induced EC apoptosis, and the zebrafish showed
normal vessels with established blood circulation (data not shown),
and a normal EC phenotype (Figure 1e, Figure S1, c, d). In
contrast, the human NRP–1 mRNA lacking its three C-terminal
amino acids (SEA-COOH) failed to block zebrafish NRP-1
knockdown-induced vessel defects, nor did it abrogate EC
apoptosis (Figure 1e, Figure S1, c, d). This suggests the functional
importance of SEA-COOH in NRP-1-mediated EC survival.
We also investigated the dynamics of apoptosis in the zebrafish
embryo. As shown in Figure 1f and Figure S1e, knockdown of
NRP-1 revealed EC apoptosis as early as 24hpf embryos, which
continued until 48 hpf. The early stage embryo had more
apoptotic cells than the late stage embryo. Taken together, these
results indicate that NRP-1 mediates EC apoptosis in zebrafish
angiogenesis, and that its C-terminal three amino acids (SEA-
COOH) are required for the function.
GIPC conveys NRP-1-mediated EC survival signaling
Based upon the above findings, we set out to further determine
downstream pathways and the role of the involved key signaling
molecules in NRP-1-mediated EC survival. Because our previous
data showed that the C terminus of the RGS-GAIP (regulators of
G-protein signaling-Ga interacting protein)-interacting protein,
GIPC (also called NRP-1 interacting protein, NIP) can function as
an adaptor protein to interact with the C-terminal three amino
acids of NRP-1 (SEA-COOH) through its PDZ domain, and can
then convey the NRP-1 signal to regulate EC migration and
zebrafish angiogenesis [19], we first sought to address the role of
GIPC in NRP-1-mediated EC survival. For this purpose, we
knocked down GIPC in HUVEC using RNA interference-
mediated silencing. After identifying that GIPC siRNA specifically
and effectively silenced the expression of GIPC, but not that of
NRP-1 or VEGFR-2 (Figure 2a), we then carried out apoptosis
assays in HUVEC transduced with EGNP-1. We found that
silencing of GIPC resulted in an increase in the percentage of
apoptotic cells in HUVEC and also had marked morphological
effects on the EC, including cytoplasmic shrinkage and cell
retraction (Figure 2b, Figure S2a). To examine this result in more
detail, we analyzed the percentage of apoptotic cells with flow
cytometry. Indeed, we observed a notable difference in apoptosis
between GIPC knock-down HUVECs and without GIPC knock-
down HUVECs (Figure 2c). Necrotic/late-apoptotic and early
apoptotic cells were significantly increased by increasing the amount
ofGIPCsiRNA. Theseresults were subsequently confirmed in vivo in
our zebrafishmodel.ZebrafishGIPCmorpholinos (1.5ng and4.5ng)
were injected into TG(fli1:egfp) embryos at the 1-4-cell stage. This
not only disturbed the formation of the dorsal longitudinal
anastomotic vessel (DLAV) and subintestinal vein (SIV) as described
in our previous study [19], but also resulted in a significant increase
in EC apoptosis, as revealed by TUNEL staining (Figure S2, b, c;
Figure 2d). Additionally, circulation in the DLAV and SIV was
diminished or blocked (data not shown). The body size was reduced
as well (Figure 2d). These phenotypes resemble those from zNRP-
1a/1b knockdown, which suggests that zGIPC is involved in the
survival signaling pathway of NRP-1. Furthermore, we found that
the GIPC-mediated EC apoptotic phenotype could be rescued with
human GIPC mRNA (Figure S2, b, c; Figure 2d), whereas
coinjection of hGIPCDPDZ mRNA with the zGIPC morpholino
did not rescue the zebrafish GIPC knockdown-induced EC
apoptotic phenotype. In summary, these results suggest that GIPC
is involved in NRP-1-mediated EC apoptosis, and that the PDZ
domain of GIPC plays an important role in this function, probably
byinteracting with the C-terminaldomainof NRP-1 (SEA-COOH).
NRP-1-mediated EC survival requires PI3K/Akt
activation
Since the survival signal mediated by various growth factors and
cytokines may be dependent upon the phosphatidylinositol 3-
kinase (PI3K)/Akt signaling pathway [31,30], we investigated the
possible regulatory role of PI3K/Akt in NRP-1-mediated survival.
We first determined the role of PI3K in NRP-1-mediated EC
survival signaling. As assessed by the number of apoptotic cells,
after treatment of EGNP-1-transduced HUVEC with Ly294002 (a
PI3K inhibitor, 25 mM) we observed a significant increase in
HUVEC apoptosis (Figure 3a, Figure S3a), which suggests that
blockage of PI3K almost completely impedes the survival effect of
NRP-1. It is known that PI3K contains a kinase subunit (p110) and
NRP-1 and p53/Caspases Axis
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signaling pathways [32]. The p85 adaptor subunit is known to
form a constitutive heterodimer with the p110 catalytic subunit.
Ligand-activated receptors interact with the p85 subunit, releasing
the p110 subunit in an active form. In this study, we further used
the dominant negative mutants of the p85 subunit (p85(DN)) and
the constitutively activated mutant of PI3K (p110CAAX) to
determine whether PI3K was required for EGNP-1-mediated EC
survival. Our results showed that the co-transduced HUVEC
expressed similar levels of EGNP-1 (data not shown), but the co-
transduction of HUVEC with EGNP-1 and p85(DN) increased
EC apoptosis compared to HUVEC co-transduced with EGNP-1
and LacZ (Figure 3a, Figure 3Sa). However, co-transfection of
p110CAAX with EGNP-1 resulted in a slightly decreased level of
EGF-induced, EGNP-1-mediated EC apoptosis. Flow cytometry
also showed a similar result to that found with TUNEL: both
Ly294002 and p85(DN) induced more EC apoptosis, especially
late apoptosis (Figure 3b). These results indicate that the anti-
apoptotic activity of NRP-1 on EC is mediated through PI3K.
It is known that the stimulation of growth factor receptor-
induced PI3K activation mediates an increase in 3-poly-phos-
phoinositides, which in turn activates downstream effectors, such
as the serine/threonine kinase Akt/protein kinase B (Akt/PKB)
[32–34]. Therefore, we tested whether the PI3K effector protein
Akt is involved in the survival response. We first co-transfected
HUVEC with EGNP-1 and wild-type Akt or its two mutant forms,
Akt(DN) (a dominant negative Akt mutant) and Akt(Active) (a
constitutively activated Akt mutant), respectively. As revealed in
Figure 3c and Figure 3Sb, Akt(Active) promoted EC survival to
levels similar to those seen in EGNP-1 transduced HUVEC grown
in the presence of EGF or 10% serum, whereas transfection of
HUVEC with the dominant-negative Akt(DN) completely in-
hibited NRP-1-mediated EC survival activity. Flow cytometry
confirmed the result showing significant high levels of late-and
early-apoptotic cells (Figure 3d) in Akt(DN) co-infected HUVEC
compared to Akt(Active) or LacZ co-infected HUVEC.
PI3k-dependent activation of Akt involves its phosphorylation at
serine 473 [34]. To further verify that Akt is involved in NRP-1-
Figure 2. GIPC is involved in NRP-1-mediated EC survival. a. Knockdown of GIPC by siRNA in HUVEC. HUVEC were transfected with siRNA against
GIPC in different concentrations. Immunoblotting was performed to quantify the expression levels of GIPC in these cells. GIPC and VEGFR-2 were
quantified as a ratio to the amount of NRP-1. b. GIPC is involved in NRP-1-mediated HUVEC survival. Apoptosis assays were performed in apoptosis-
induced HUVEC transfected with EGNP-1 and then transfected with siRNA, and followed by 10 ng/ml EGF stimulation for 48 hours. Quantitative
determination of apoptotic nuclei (n=8). Knock down of GIPC inhibits EGF-stimulated HUVEC apoptosis in a dosage-dependent manner. c. FACS
apoptosis analysis to assess the percentage of apoptotic HUVEC. All the experiments at least were repeated three times and duplicated-wells were
used for each experiment. *p,0.001, **p,0.005, ***p,0.01, ****p,0.05 in a Student’s t test. d. GIPC is involved in NRP-1-mediated EC survival in
zebrafish. Fluorescent image of embryos injected with indicated morpholinos and mRNA, then subjected to the antibody stain with anti-GFP
antibody and TUNEL assay to detect apoptosis. Insets show a magnification of apoptotic foci in the vessel. The arrows indicate apoptotic EC. i.
Control; ii. zGIPC MO (4.5 ng); iii. zGIPC (4.5 ng)+hGIPC mRNA (0.3 ng); iv. zGIPC MO (4.5 ng)+hGIPCDPDZ mRNA (0.3 ng).
doi:10.1371/journal.pone.0001161.g002
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EGNP-1-transduced HUVEC treated with 10 ng/ml EGF for Akt
activation, as indicated by phosphorylation at serine 473, using
a phospho-specific antibody. In initial time course experiments, we
found significant phospho-Akt upregulation as early as 2 minutes
with maximal activation at 10–15 minutes after exposure of
EGNP-1-transduced HUVEC to EGF (Figure 3e). The response
gradually decreased after prolonged incubation (data not shown).
As in HUVEC, the level of phospho-Akt was also upregulated in
PAEC/NRP-1 stimulated by VPF/VEGF (Figure 3e).
Finally, we evaluated the effect of PI3K depletion on the
activation of Akt. As shown by Western blot analysis, the PI3K
inhibitor Ly294002 (25 mM) completely abolished Akt activation
in response to EGF in EGNP-1-transduced HUVEC (Figure 3f),
but the VEGFR-2 kinase inhibitor IV (100 nM), which can inhibit
VEGFR-2 phosphorylation, did not influence EGNP-1-induced
Akt phosphorylation (Figure 3f). These results suggest that Akt is
a downstream effector in NRP-1-mediated EC survival signaling
and exclude the possibility of involving VEGFR-2-mediated Akt
activation in this study. In light of the above results, we conclude
that PI3K/Akt is critically involved in NRP-1-mediated EC
survival effects.
p53 and the mitochondrial apoptotic pathway axis
inactivation are involved in NRP-1-mediated EC
survival
About 13–18% of MOs used in zebrafish result in off-target effects
[35], which are represented by a signature neural death peaking at
the end of segmentation (1dpf, day post–fertilization). The
embryos display small heads and eyes, somite and notochord
defects and craniofacial defects. Collaborative information from
Dr. Stephen C. Ekker (Department of Genetics, Cell Biology, and
Development, University of Minnesota, Minneapolis) has shown
that the off-target effects of MOs are mediated through p53-
induced apoptosis. In this study, we found that knockdown of
NRP-1a/-1b in zebrafish resulted in neural death phenotype and
vessel defects, including EC apoptosis, suggesting that NRP-1
Figure 3. PI-3K/Akt is involved in NRP-1-mediated HUVEC survival. a. PI3K is involved in NRP-1-mediated EC survival signaling. Apoptosis assay was
performed in apoptosis-induced HUVEC transfected with EGNP-1 or co-transfected with EGNP-1 and p85(DN) and stimulated with or without 10ng/
ml EGF for 48hours, and then treated with LY294002 for 30 minutes, accordingly. Apoptotic nuclei were determined quantitatively (n=8). b. FACS
apoptosis analysis to quantify the percentage of apoptotic HUVEC. c. Akt is involved in PI3K-mediated NRP-1 survival signaling in EC. Apoptosis assays
were performed in apoptosis-induced HUVEC transfected with EGNP-1 or co-transfected with EGNP-1 and Akt(DN) or Akt(Active) and stimulated with
or without 10ng/ml EGF. Apoptotic nuclei were determined quantitatively (n=8). d. FACS apoptosis analysis to determine the percentage of
apoptotic HUVEC. All the experiments at least were repeated three times and duplicated-wells were used for each experiment. *p,0.001, **p,0.005,
***p,0.01 in a Student’s t test. e. Akt phosphorylation by NRP-1/EGNP-1 activation. HUVEC were transfected with EGNP-1 and then stimulated with
EGF. Immunoblotting with anti-phospho-Akt was carried out to quantify the expression levels of phospho-Akt in these cells. b-Actin was used as
a loading control f. The influence of PI3K depletion and VEGFR-2 phosphorylation inhibition on EGNP-1-mediated Akt activation. Immunoblotting was
performed in HUVEC transfected with EGNP-1 and then treated with Ly294002 or VEGFR-2 Kinase inhibitor IV. Phospho-Akt and Akt were quantified
as a ratio to the amount of b-Actin
doi:10.1371/journal.pone.0001161.g003
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suggest p53 is involved in NRP-1-mediated antiapoptotic effects.
The latter seems more convincing in this study because we also
observed that the morphant phenotypes from NRP-1 knockdown
were rescued by human NRP-1 mRNA. It is quite likely that
NRP-1 is specifically involved in cell death. For this purpose,
Mdm2 MO and p53 MO co-injection embryos were used as
controls. As we have shown previously, NRP-1 MOs induced
vessel defects and EC apoptosis. In addition, we also observed tail
and body axis, and neuron apoptosis (data not shown), that are
very similar to the neural death phenotype induced by off-target
effects of MOs. Interestingly, after co-injecting p53 MO with
NRP-1a/-1b MOs, we found that knockdown of p53 mostly
alleviated off-target neural death compared to the positive control,
while the vessel defects by knockdown NRP-1 were also mostly
rescued (Figure 4a, Figure S4, a, b). These results suggest that p53
is involved in NRP-1-mediated EC survival.
This finding was further confirmed by investigating the effect of
NRP-1 activation on p53 expression. By stimulating EGNP-1-
transduced HUVEC with 10 ng/ml EGF, p53 protein expression
levels decreased significantly at 30 minutes to 24 hours when
compared to the control group without EGF stimulation
(Figure 4b). This indicates that the EGNP-1-mediated EC
antiapoptotic effect is induced by inhibition of p53 activation.
Similar results for p53 expression level were also observed inPAEC/
NRP-1 (Figure 4b). These results support our in vivo findings.
A previous study reported that effective recruitment of Akt by
appropriate survival signals may lead to activation of Mdm2,
inactivation of p53, and eventually inhibition of p53-dependent
apoptosis [36]. We, therefore, further investigated whether p53 is
downstream of PI3K/Akt in NRP-1 signal. As shown in Figure 4c,
the inhibition of PI3K with Ly294002 or blockage of Akt with the
dominant negative mutant of Akt (Akt(DN)) reversed the
expression of p53 to a higher level in EGNP-1-transduced
HUVEC stimulated with EGF, which suggests that p53 is, in
fact, downstream of PI3K/Akt in NRP-1-mediated EC survival.
Caspases are involved in both the mitochondria-independent
(extrinsic) and the mitochondria-dependent (intrinsic) pathways
[37,38], the two main pathways of cell death signaling in biological
systems.p53canregulatethesecretionofcytochromectoinitiatethe
mitochondria-dependent pathway, leading to the activation of
caspase-9 then caspase-3 followed by apoptosis [39]. p53 also
regulates a series of genesthat initiate the mitochondria-independent
pathway, resulting in caspase-8 and -3 activities and apoptosis [40].
For these reasons, we sought to determine whether NRP-1’s anti-
apoptosis is associated with inactivation of caspases. We examined
the cleavage of the key apical caspases in the extrinsic pathway
(caspase-8) and in the intrinsic pathway (caspase-9) as well as the
cleavage and activity of caspase-3, which is the major executioner
protease for both pathways. Cleavage of caspase zymogens is
instrumental to the activation of caspase-3 and directly follows
proximity-induced activation of apical caspases, thus contributing to
their sustained activity [37,41]. Pro-caspase-9 is the apical caspase of
the intrinsic pathway and is efficiently processed within the
apoptosome [37]. In this study, cleavage of pro-caspase-9 was
induced by serum starvation for 24 hours in EGNP-1-transduced
HUVEC. Western blot analysis showed the full length caspase-9
(47 kDa) and a cleaved fragment (37 kDa) (Figure 4d). Following
30 minutes to 24 hours of stimulation with EGF in these cells, we
found that the levels of cleaved caspase-9 decreased, as indicated by
the concomitant increase of the pro-caspase band and the decreased
formation of the p35 fragment (Figure 4d). Activated or cleaved
caspase-3 (17 and 19 kDa) is crucial for the induction of apoptosis.
After 24 hours serum starvation, pro-caspase-3 is proteolytically
cleavedtogeneratea p19 signature fragmentinEGNP-1-transduced
HUVEC, but the cleavage level decreased following EGF
stimulation (as shown in Figure 4d). In this study, cleavage of
caspase-8 was not detected (data not shown). These results indicate
that sustained activation of NRP-1 inhibits caspase-9, and
consequently directly suppresses the cleavage of its preferred
substrate, caspase-3, therefore may reduced EC apoptosis. Taken
together, the above results confirm that the NRP-1-mediated EC
anti-apoptotic affects occur through the axis inactivation of p53 and
mitochondrial apoptotic pathway.
Induction of p21 is involved in NRP-1-mediated EC
survival
p53 is a transcription factor, and its loss results in changes in the
expression of downstream target genes. One such target gene is
p21
Cip1/WAF1(p21), which we examined in this study. As shown in
Figure 5a, we observed a significant increase in p21 protein levels
from 30 minutes to 24 hours after EGF stimulation in EGNP-1-
transduced HUVEC or VPF/VEGF stimulation in PAEC/NRP-
1. Obviously, this increased p21 expression level is independent of
p53 inhibition. The cyclin kinase inhibitor p21 was initially
believed to be an inhibitor of cell cycle progression, but has since
been shown to have additional functions other than CDK
inhibition. A recent study reported that AKT/PKB phosphory-
lation of p21 enhances the protein stability of p21 and promotes
cell survival [42]. Based on this evidence, we first examined
whether NRP-1 activation can induce p21 phosphorylation. We
used two antibodies against the potential AKT/PKB phosphor-
ylation sites of p21, Thr
145 and Ser
146. Figure 5b demonstrates
that p21 is phosphorylated by EGNP-1 in the two positions.
Furthermore, we tested whether the increased expression level of
p21 results from NRP-1-mediated PI3K/AKT activation. Indeed,
our results showed that there was a reduced expression level of p21
in LY294002 treated or Akt(DN) co-infected HUVEC, compared
to the control HUVEC infected only with EGNP-1. Meanwhile,
we found that the phosphorylation levels of p21 at sites Thr
145 and
Ser
146 were also reduced (Figure 5c). Together, these data suggest
that NRP-1-mediated EC survival occurs through Akt/PKB
activation-induced phosphorylation and up-regulation of p21.
Modulation of FoxO transcription factor activation
in NRP-1-mediated EC survival signaling
Studies have suggested that PI3K-mediated Akt activation in
mammals negatively regulates the Forkhead box class O (FoxO)
subfamily of Forkhead transcription factors [43,44]. Akt mediates
phosphorylation of FoxO proteins [44,45], which prevents their
nuclear translocation, thereby inhibiting their transcriptional
competence. Studies in mammalian cells have shown that the
overproduction of FoxO1 (FKHR), FoxO3a (FKHRL1), and
FoxO4 (AFX) induces either cell cycle arrest or apoptosis [44,46].
Based upon these findings, we decided to address whether PI3K/
Akt-mediated NRP-1 survival signaling occurs through inhibition
of FoxO transcription factors. HUVEC are known to express
FoxO1 and FoxO3a, whereas FoxO4 could not be detected [47].
We therefore focused on these two FoxO transcription factors. As
we expected, Western blot analysis showed that 10ng/ml EGF or
VPF/VEGF stimulation resulted in a significant increase in the
phosphorylated forms of FoxO1a and FoxO3a in the EGNP-1-
transduced HUVEC or PAEC/NRP-1 (Figure 6a). Furthermore,
depletion of PI3K or blockage of Akt resulted in a significant
decrease in the phosphorylated forms of FoxO1 and FoxO3a
proteins in EGNP-1-transduced HUVEC (Figure 6b). Our results
NRP-1 and p53/Caspases Axis
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PI3K/Akt through the inhibition of FoxO1 and FoxO3a.
DISCUSSION
In this study, we show a novel function for NRP-1, which can
mediate VPF/VEGF-induced EC survival independent of
VEGFR-2. We used PAEC transfected with NRP-1 cDNA to
examine the specific function of NRP-1. PAEC/NRP-1 was
a generous gift of by Dr. Shay Soker (Molecular and Cell Biology,
Wake Forest Institute for Regenerative medicine). Previously,
Soker et al. established stable cell lines synthesizing neuropilin-1
(PAEC/NRP-1) and characterized VEGF165 binding to NRP-1
in the cell [48]. PAEC were chosen for this study due to their lack
of expression of any VPF/VEGF receptors [49]. To explore the
possibility that NRP-1 might transduce VPF/VEGF signaling
alone, NRP-1 must be selectively activated, since VPF/VEGF
receptors VEGFR-1 and VEGFR-2 are also expressed in EC. To
do so, we used the chimeric receptor EGNP-1 by replacing the
extracellular domains of NRP-1 with the N-terminal domain of
EGFR. At #80% confluence, early passage HUVEC doesn’t
express EGFR, and therefore, the fusion receptor can be used to
distinguish the signaling pathway that is mediated by NRP-1 [16].
This might seem to be scant evidence because NRP-1 might form
a complex with VEGFR-2 through its intracellular domain.
However, previously using EGNP-1, together with co-transducing
HUVEC with EGDR mutants or blocking VEGFR-2 with an
anti-VEGFR-2 antibody, we demonstrated that NRP-1 mediates
HUVEC migration independent of VEGFR-2 [16]. This suggests
that NRP-1 can indeed function independently of VEGFR-2 in
VPF/VEGF signaling and supports our findings in this study. The
current understanding of NRP-1 function is primarily based upon
studies of its extracellular domain. However, the chimeric receptor
EGNP-1, though it lacks the extracellular domain of NRP-1, has
been shown to be involved in EC survival. This hints there may be
a distinguishing pathway whereby NRP-1 mediates EC survival
Figure 4. p53 inactivation in NRP-1-mediated EC survival. a. p53 is involved in NRP-1-mediated EC survival in zebrafish. Fluorescent image of
embryos injected with indicated morpholinos and subjected to the antibody stain with anti-GFP antibody and TUNEL assay to detect apoptosis;
Insets show a magnification of apoptotic foci in the vessel. The arrows indicate apoptotic EC. i. Control; ii. zNRP-1a/1b MOs (4.5 ng+4.5 ng); iii. zNRP-
1a/1b MOs (4.5 ng+4.5 ng)+zp53 MO (9.0 ng); iv. zMdm2 MO (4.5ng); v. zMdm2 MO (4.5 ng)+zp53 MO (9.0 ng). b. NRP-1/EGNP-1-mediated p53
inactivation. EGNP-1 transduced HUVEC or PAEC/NRP-1 were subjected to EGF or VEGF for the indicated times and their lysates were immunoblotted
for p53 with b-actin as a loading control. c. p53 is the downstream signaling molecule of PI3K/Akt in EGNP-1-mediated EC survival. HUVEC were
transfected with EGNP-1 then treated with Ly294002 or co-transfected with EGNP-1 and Akt(DN). Immunoblotting was performed to determine p53
expression level. d. Inhibition of mitochondrial apoptotic pathway in EGNP-1-mediated EC survival. Immunoblotting was carried out in EGNP-1
transduced HUVEC stimulated with EGF at indicated times to assess the activation of caspase-9 and caspase-3. p53 and caspases were quantified as
a ratio to the amount of b-Actin *p,0.001, **p,0.005, ***p,0.01, ****p,0.05 in a Student’s t test.
doi:10.1371/journal.pone.0001161.g004
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signaling. Indeed, our published data have shown that the C-
terminal three amino acids of NRP-1 (SEA-COOH) can interact
with GIPC and are involved with NRP-1-mediated EC migration
[19], whereas we failed to identify VEGFR-2 in the complex of
NRP-1 and GIPC (data not shown). These facts, together with the
Figure 5. Induction of p21 through PI3K/Akt is involved in the survival signaling of NRP-1. a. The activation of NRP-1/EGNP-1 increased p21
expression. EGNP-1 transduced HUVEC or PAEC/NRP-1 were subjected to EGF or VEGF for the indicated times and their lysates were immunoblotted
for p21 with PLC-c as a loading control. b. The activation of EGNP-1 induced p21 phosphorylation at its Tyr
145 and Ser
146 sites. Immunoblotting was
performed with anti-p21Tyr and anti-p21Ser in EGNP-1 transduced HUVEC stimulated by EGF for the indicated times. c. Akt mediates the
phosphorylation of p21 in EGNP-1-mediated signaling. HUVEC were transfected with EGNP-1 then treated with Ly294002 or co-transfected with
EGNP-1 and Akt(DN). Immunoblotting was performed to quantify the expression and activation of p21. p21 and phospho-p21 were quantified as
a ratio to the amount of PLC-c.* p,0.001, **p,0.005, ***p,0.01, ****p,0.05 in a Student’s t test.
doi:10.1371/journal.pone.0001161.g005
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acids and GIPC are essential for NRP-1-mediated EC survival,
support the existence of an independent signaling pathway for
NRP-1-mediated VPF/VEGF function. Overall, these results
indicate that NRP-1 can mediate VPF/VEGF-dependent EC
survival as an independent receptor.
Our previous study demonstrated that GIPC functions as a key
adaptor protein that is involved in NRP-1-mediated EC migration
and angiogenesis [19]. Similarly, we found that knockdown of
GIPC in this study suppresses NRP-1-mediated anti-apoptotic
effects in HUVEC and increases EC apoptosis in the zebrafish
model, suggesting that GIPC addresses the same signaling
pathway as NRP-1 in NRP-1-mediated EC survival. Consequent-
ly, how GIPC conveys NRP-1 survival signaling in EC is obviously
an important issue that should be targeted.
In this study, we found that the PI3K inhibitors Ly294002 and
p85(DN), a dominant negative mutant of the p85 subunit, reduced
levels of NRP-1/EGNP-1-dependent survival. These observations
indicate that PI3K is involved in NRP-1-mediated EC survival
signaling, which is consistent with the findings by Bachelder et al.
that NRP-1 supported VPF/VEGF autocrine function and
promoted breast carcinoma cell survival by stimulating the PI3K
pathway [29]. Activation of PI3K phosphatidylinositol-3, 4, 5-
triphosphate positively regulates Akt by binding to the pleckstrin
Figure 6. Involvement of transcription factors FoxO1 and FoxO3a in NRP-1-mediated EC survival signaling. a. Phosphorylation of FoxO1 and
FoxO3a in NRP-1 survival signaling. After EGF stimulation of EGNP-1-transduced HUVEC or VEGF stimulation of PAEC/NRP-1 for the indicated times,
the protein levels in cell extracts of FoxO1 and FoxO3a were assessed by immunoblotting. b. PI3K/Akt depletion resulted in reduction of FoxO1 and
FoxO3a phosphorylation. HUVEC were transfected with EGNP-1, then treated with Ly294002 or co-transfected with EGNP-1 and Akt(DN).
Immunoblotting was performed to determine the phosphorylation level of FoxO1 and FoxO3a with b-Actin as a loading control. phospho-FoxOs and
FoxOs were quantified as a ratio to the amount of b-Actin. *p,0.001, **p,0.005, ***p,0.01, ****p,0.05 in a Student’s t test.
doi:10.1371/journal.pone.0001161.g006
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Akt phosphorylation levels increased after EGF stimulation of
EGNP-1-transduced HUVEC, and that such activation could be
inhibited by the PI3K-specific inhibitor Ly294002 but not
influenced by inhibiting VEGFR-2 phosphorylation. This con-
firms that NRP-1 survival signaling induces PI3K-dependent Akt
phosphorylation. The ability of activated Akt to promote survival
has been found in fibroblasts [51] and heochromocytoma cells [52]
and neuronal cells [32]. In accordance with these findings, we found
that the kinase-inactive Akt mutant (Akt(DN)), that has been
suggested to act in a dominant-negative manner [53], blocks NRP-
1-mediated survival activity on EC. This finding constitutes the
further demonstration of a role played by the PI3-kinase/Akt
pathway in mediating a NRP-1 survival activity. Despite the
additional information provided by the above results, how PI3K is
activatedinNRP-1survivalsignalingstillremainsunknown.p85,the
regulatory subunit of PI3K, contains two SH2 domains and a SH3
domain. The SH2 domain of p85 is responsible for interaction with
phosphorylated tyrosine in the context of motif YXXM [54,55].
However,unlikeVEGFR-2,theintracellulardomain ofNRP-1lacks
the YXXM motif. Since GIPC is a central adapter protein for NRP-
1 signaling, it is tempting to speculate that GIPC may function as an
adaptor molecule, mediating the activation of p85 by NRP-1, which
is currently under investigation.
Given that a transformed approach might alter signaling
pathways (Dr. Stephen C. Ekker, Department of Genetics, Cell
Biology, and Development, University of Minnesota, Minneapo-
lis), especially those that regulate cell survival, the involvement of
p53 in regulating the apoptotic pathway suppressed by survival
signals from NRP-1 was addressed more comprehensively by both
in vivo and in vitro studies in this work. In the zebrafish model, EC
apoptosis and vessel defects resulting from the loss of NRP-1 are
recovered when p53 expression is downregulated. This suggests
that p53 acts upon downstream components of a NRP-1
activation-induced survival cascade. The p53 pathway is com-
posed of hundreds of genes and their products that respond to
a wide variety of stress signals, including apoptosis and cell cycle
arrest. The former involves caspase cascade while the latter is
mediated by p21. Decreased levels of p53 might suppress caspase
cleavage and therefore downregulate apoptosis. Indeed, our in vitro
data found that activating NRP-1 decreases the expression of p53,
caspase-9 and caspase-3, which confirms our in vivo observations.
Our findings that NRP-1-induced cell survival more directly
affects caspase-9, then caspase-3, but not caspase-8 cleavage, also
supports the concept that phospholipases may be primarily
involved in the intrinsic (mitochondria-dependent) arm of the
bifurcate pathways of apoptosis mediated by death receptors. In
addition, the data shown here that p53 is the downstream
signaling molecule of PI3K/Akt hints that Mdm2 may be another
considerable signaling component in NRP-1 survival signaling in
EC, thereby connecting connects PI3K to p53.
p21 was originally isolated as a p53-inducible protein and
identified as an inhibitor of cyclin-dependent kinases (CDKs), and
thus thought to function as a critical regulator of the cell cycle [56–
58]. However, a number of previous studies suggested that p21
levels were alternatively regulated by p53-independent mech-
anisms. Serum and other growth factors might be involved with
the up-regulation of p21 levels in various cell types [59,60]. The
activator of the PI3K pathway, EGF, increased p21 levels by
increasing the half-lives of both transcript as well as protein [61].
Additionally, the PI3K pathway was involved with the modulation
of p21 levels [62,63]. Inhibitors of the PI3K pathway reduced the
level of p21 in both cases. Moreover, recent investigations have
clearly demonstrated that p21 also plays a role in allowing cell
cycle transit as well as preventing apoptosis. Many late stage,
rapidly proliferating tumors show a profound elevation in the
levels of p21, which is counterintuitive in light of the proposed
inhibition of cell cycle progression mediated by p21 [64-66]. The
pro-survival activity of p21 in cells treated with chemotherapeutic
agents such as taxol also argues for a role for this protein in the
protection of tumors in vivo [67,68]. The similar pro-survival effect
is also observed in terminally differentiated cells such as myoblasts
[69], hematopoietic stem cells [70], and macrophages [71]. An
exciting finding shown by Li et al., indicated that Akt phosphor-
ylation of p21 at sites
145 and Ser
146 resulted in increased p21
stability as well as enhanced glioblastoma cell survival [42].
Notably, the results from our current study are consistent with
these observations, confirming a crucial role for p21 as an anti-
apoptotic protein, and also providing evidence that p21 levels can
be regulated directly by PI3K/Akt. In addition, the elevated levels
of p21 may also partly result from activated PI3K/Akt-induced
caspase-3 inactivation, which reduces caspase-3-mediated p21
cleavage. This is consistent with a previous study that caspase-3-
mediated cleavage of p21 during the apoptotic process sends
growth-arrested cells to apoptosis[72]. While this novel role of p21
is evolving, a recent study revealed that p21 blocks irradiation-
induced apoptosis downstream of mitochondria by inhibition of
cyclin-dependent kinase-mediated caspase-9 activation [73]. Since
the mechanisms by which p21 interferes with the death machinery
are still largely unknown, however, this remains our current focus.
FoxO transcription factors are key regulators of cell fate. The
mammalian FoxO family of transcription factors FoxO1, FoxO3a,
and FoXO4 are major substrates of the protein kinases PKB (Akt).
Activation of the PI3K pathway blocks the function of all 3 FoxO
members by Akt-dependent phosphorylation of three conserved
residues, which relay PI3K signals to target genes [74,75]. A recent
study has shown that FoxO1 and FoxO3a are the predominant
FoxO isoforms expressed in mature EC [47]. In this study, we
found that NRP-1 induced the rapid phosphorylation of FoxO1
and FoxO3a and was mediated by activated PI3K/Akt. These
data suggest a requirement for FoxO1 and FoxO3a inactivation
during NRP-1-induced EC survival and are consistent with
previous studies into the roles of FoxO1 and FoxO3 in the
induction of cell apoptosis [44,76]. The mechanism whereby
FOXO proteins promote apoptosis in different cell types appears
surprisingly diverse and includes induction of death-receptor
ligands (e.g. FasL) and proapoptotic factors (e.g. Bim) as well as
repression of cytoplasmic (e.g. c-FLIP) and mitochondrial anti-
apoptotic proteins (e.g. Bcl-2 and Bcl-xL) [77–80]. How FoxO1
and FoxO3a function in PI3k/Akt-dependent NRP-1 survival
signaling in EC has not been fully defined in this study and
remains to be elucidated.
In summary, after finding that NRP-1 can mediate VPF/
VEGF-induced EC survival independent of VEGFR-2, our results
also highlight, for the first time, the distinct signaling pathways of
NRP-1 in VPF/VEGF-induced survival effects in EC by
connecting NRP-1 and GIPC to activation of PI3k/Akt and
subsequent inactivation of p53 pathways and FoxOs, as well as
activation of p21. Based upon these findings, we proposed the
working model in detailed in Figure 7.
What is emerging from this study, also in the light of reports
from our previous studies and others, is that NRP-1 can function
alone to mediate VPF/VEGF signaling. The consistency of our
results supports the two current hypotheses for NRP-1 function in
VPF/VEGF signaling in EC: either that NRP-1 is involved in
VPF/VEGF-induced EC function by acting as a VEGFR-2 co-
receptor, or alternatively, as a functional receptor alone. Not only
this, recognizing the mechanistic aspects of coreceptor-based or
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implications for other ligand guidance and complicated receptor-
mediated events which form the basis of key biological functions.
In addition, the multiple pathways involved in NRP-1-mediated
VEGF survival signaling indicate a degree of complexity that is
paralleled by the emerging complexity of interaction between
VEGF ligands and their receptors, and the downstream signaling
pathways they mediate.
To the best of our knowledge, both the VEGFR-2 signal alone, as
well as NRP-1 acting in concert with VEGFR-2, are involved in
VPF/VEGF-induced EC survival in vivo. As a consequence, NRP-1
signaling alone only partly determines EC fate. This implies that an
understanding of the role of NRP-1 only provides part of the picture
of VPF/VEGF survival signaling. However, given our increasing
understanding of NRP-1, we can generate a more complete scenario
of how the signaling molecule determines cell behavior.
MATERIALS AND METHODS
Materials
Human EGF, human VEGF, primary HUVEC, EGM-MV bullet
kit and EC basic medium (EBM) were purchased from CLonza
(San Diego, CA). F12 Medium was purchased from GIBCO
(Carlsbad, CA). Optimem medium and lipofectamine 2000 were purchased
from Invitrogen (Carlsbad, CA). GIPC siRNA was purchased from
Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). The following
antibodies were used: Goat polyclonal antibody against the NRP-
1-C-terminal domain, anti-GIPC, anti-p53 and anti-p21 were
purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA);
anti-Akt1/PKB, anti-phospho-Akt1/PKB(Ser473), anti-FoxO3a
(FKHRL1), and anti-phospho-FoxO3a (FKHRL1, Ser253), were
purchased from Upstate Biotechnology (Waltham, MA); anti-
FoxO1a (FKHR), anti-phospho-FoxO1a (FKHR, Ser256), anti-
cleaved caspase-3, anti-caspase-8, and anti-caspase-9 were pur-
chased from Cell Signaling Technology (Beverly, MA); and anti-ß-
actin was purchased from Sigma Chemical Company (St. Louis,
MO). Anti-GFP antibody was purchased from Invitrogen. The
quantification of protein was performed with a digital analysis of
protein bands (TIFF images) using UN-SCAN-IT software (Silk
Scientific, Orem, UT). VEGFR-2 Kinase Inhibitor IV was
purchased from Calbiochem (San Diego, CA).
Cell culture and treatment
Parental PAEC and PAEC expressing NRP-1 (PAEC/NRP-1)
[were kindly provided by Dr. Shay Soker (Molecular and Cell
Biology, Wake Forest Institute for Regenerative medicine) and
were grown in F12 medium containing 10% FCS and GPS[48].
HUVEC (CLonza, San Diego, CA) were cultured as described
previously. HUVEC were grown on 30 mg/ml vitrogen-coated
dishes using the EGM-MV Bullet Kit (5% fetal bovine serum [FBS]
in EBM with 12 mg/ml bovine brain extract, 1 mg/ml hydrocor-
tisone, and 1 mg/ml GA-1000).
HUVEC (passage 3 or 4) that were ,80% confluent were used
for most experiments. Apoptosis was induced by deprivation using
EBM supplemented with 0.1% BSA for 24 h. After that, cells were
exposed to 10ng/ml VPF/VEGF or EGF in the same medium for
48 hours and then used for apoptosis testing.
Zebrafish lines and maintenance
Zebrafish were maintained and bred as described previously[81]
(All experiments were performed using the TG(fli1:egfp)y1 l
transgenic line that has been described previously[82] (Embryos
were staged according to Kimmel et al[83].
TUNEL assay
Detection and quantification of EC apoptosis was performed using an
In Situ Cell Death Detection Kit, TMR red Roche, Nutley, NJ). The
assay was performed following the manufacturer’s protocol. Samples
were dechorionated and fixed in 4% paraformaldehyde for 1 hour at
room temperature. Then they were washed with PBS twice and
permeabilizedwith0.1% sodiumcitrate, 0.1% TritonX for 2 minutes
on ice. After washing twice in PBS, samples were incubated with the
reactionmixturecontainingtheterminal deoxynucleotidyltransferase
and TMR labeled nucleotides for 1 hour in the dark at 37uC. The
reaction was stopped by washing with PBS three times. Terminal
deoxynucleotidyl transferase catalyzed the incorporation of labeled
nucleotides to 3-OH DNA and ends in a template-independent
reaction. The fluorescent signal was visualized and imaged using
a Zeiss Axioplan 2 microscope coupled to an Apotome, using
AxioVision 4.2 software (Zeiss). Z-stacks were superimposed using
Extended Focus feature of the software.
Flow cytometry analysis
Cells (5610
4) were seeded on the slide cover in six-well culture plates
and treated for 48 h with VPF/VEGF (10 ng/ml) in medium
containing 0.1% FBS. Cells were washed with PBS and apoptosis
was assessed using the Annexin V-FITC/PI apoptosis detection kit
(BioVision, Inc., Mountain View, CA) according to the manufac-
turer’s instructions. The respective proportions of apoptotic cells and
necrotic/late-apoptotic cells were measured on 20,000 cells with
a FACS Calibur analysis system (Becton Dickinson, CA, USA).
RNA interference
HUVECs at 70% confluency will be transfected in optimem
medium with the siRNA duplexes using lipofectamine 2000
(Invitrogen). After 4 hours the transfection medium will be
removed, the cells will be washed twice with PBS and then
maintained in complete HUVEC medium for 48 hours before
performing experiments with VPF/VEGF stimulation as above.
Figure 7. The working model of NRP-1-mediated EC survival. NRP-1
mediates VPF/VEGF-induced EC survival effects in EC by connecting
NRP-1 and GIPC to activation of PI3k/Akt and subsequent inactivation of
p53 pathways and FoxOs, as well as activation of p21.
doi:10.1371/journal.pone.0001161.g007
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Morpholinos were designed targeting splice donors of the specific
genes to efficiently block pre-mRNA splicing. Zebrafish NRP-1a/
NRP-1b MOs, p53 MO, and MDm2 MO were designed as
described. We purchased Morpholino antisense oligonucleotides
from Gene Tools, Inc, (Philomath, OR). The sequences are
available upon request. The injection solution was prepared as
described. Morpholino solutions with 3.0 and 6.0 ng MOs were
injected into zebrafish embryos at the 1-4 cell stage, respectively.
Embryos were examined for EC apoptosis and vascular defects at
different time points. Quantitative RT-PCR (Ambion, Austin, TX)
was used to monitor the splicing events. All experiments were
repeated at least three times
mRNA microinjection
The human full-length NRP-1 and a construct with the last three
amino acids deleted (S-E-A), the human full-length GIPC and its
PDZ domain deletion mutant were each cloned into the pCS2 vector
respectively. The transcribed mRNAs were injected together with the
NRP-1 morpholino or alone into 1-4 cell staged embryos. By using
a splicing donor morpholino, it is possible to reduce the endogenous
expression of the gene, without disturbing the expression of ectopic
mRNAs. All experiments were repeated at least three times.
Antibody staining
4% paraformaldehyde-fixed zebrafish embryos were permeabi-
lized with Proteinase K, then incubated with anti-GFP antibody at
4uC overnight. After washing with PBST, the zebrafish embryos
were used for TUNEL staining.
Detection of apoptotic EC in zebrafish
To examine the functions of NRP-1 in zebrafish EC apoptosis,
morpholinos were injected into a Fli-GFP transgenic fish line,
where all of the EC are labeled with GFP. Then, zebrafish
embryos were fixed at different time points after injection (24, 30,
36, 42 and 48 hpf) with a freshly prepared fixation solution (4%
PFA) overnight at 4uC. Antibody-stain with anti-GFP antibody
was performed to increase the fluorescence green signal in vessel
that has been reduced due to fluorescence diffusion by fixation.
Apoptosis was characterized with similar steps as described above
using the In Situ Cell Death Detection Kit, TMR red (Roche).
Antibody-stained embryos were incubated with the reaction mixture
directly. Imaging of blood vessels in TG(fli1:egfp)y1 embryos was
performed usinga Zeiss confocal laser microscope. Transmitted light
images were obtained with a Leica MZ FLIII microscope equipped
with a Nikon COOLPIX8700 digital camera. The identity of the
apoptotic cells was confirmed by using the red channel where EC
would be labeled by Fli-GFP signal.
Quantitative RT-PCR
Total RNA was extracted using Trizol reagent (Invitrogen,
Carlsbad, CA) Quantitative RT-PCR was carried out on 200ng
RNA using the lightCycler RNA amplification Kit SYBR Green
(Roche) in a LightCycler 2.0 Instrument, following the manu-
facturer’s protocols.
SUPPORTING INFORMATION
Figure S1 NRP-1 mediates VPF/VEGF-induced EC survival.
NRP-1 mediates VPF/VEGFinduced PAEC survival. TUNEL
assay was performed in PAEC or PAEC/NRP-1 stimulated with
or withour 10 ng/ml VPF/VEGF for 48 hours. (i) PAEC/
5%FBS. (ii) PAEC/0.1% FBS. (iii) PAEC/0.1% FBS/VEGF; (iv)
PAEC/NRP-1/5%FBS; (v) PAEC/NRP-1/0.1% FBS; (vi)PAEC/
NRP-1/0.1%FBS/VEGF. b. EGNP-1 mediates HUVEC survival;
the C-terminal three amino acids of NRP-1 are essential for this
function. TUNEL assay was performed in apoptosis-induced
HUVEC transfected with EGNP-1 or EGNP-1DSEA and
stimulated with or without 10 ng/ml EGF for 24 hours. (i)
HUVEC/5% FBS. (ii) HUVEC/0.1%FBS. (iii) HUVEC/EGNP-
1/0.1%FBS. (iv) HUVEC/LacZ/0.1%FBS/EGF. (v) HUVEC/
EGNP-1/0.1% FBS/EGF. (vi) HUVEC/EGNP-1 DSEA/
0.1%FBS/EGF. c. Determination of the quantity of apoptotic
EC nuclei in zebrafish (n.30). Fluorescent image of embryos
injected with indicated morpholinos and mRNA, then subjected to
the antibody stain with anti-GFP antibody and TUNEL assay to
detect apoptosis. i. Control; ii. Mismatch MO (4.5 ng); iii. zNRP-
1a/1b MOs (1.5 ng+1.5 ng); iv. zNRP-1a/1b MOs (4.5 ng+
4.5 ng); v. zNRP-1a/1b MOs (4.5 ng+4.5 ng)+hNRP-1 mRNA
(0.1 ng); vi. zNRP-1a/1b MOs (4.5 ng+4.5 ng)+hNRP-1 mRNA
(0.3 ng); vii. zNRP-1a/1b MOs (4.5 ng+4.5 ng)+hNRP-1DSEA
mRNA (0.1 ng); vii. zNRP-1a/1b MOs (4.5 ng+4.5 ng)+hNRP-
1DSEA mRNA (0.3 ng). d. Determination of the quantity of vessel
defects (n.30) in embryos as in c. e. Determination of the quantity
of apoptotic EC nuclei in different stage zebrafish embryos (n.20).
Fluorescent image of different stage embryos injected with
indicated morpholinos and subjected to the antibody stain and
TUNEL assay to detect apoptosis. *p,0.001, **p,0.005,
***p,0.01, ****p,0.05 in a Student’s t test.
Found at: doi:10.1371/journal.pone.0001161.s001 (4.90 MB TIF)
Figure S2 GIPC is involved in NRP-1-mediated EC survival. a.
GIPC is involved in NRP-1-mediated HUVEC survival. TUNEL
assay was performed in HUVEC transfected with EGNP-1 and
then transfected with siRNA, and stimulated with or without
10 ng/ml GEF for 48 hours. (i) HUVEC/5%FBS. (ii) HUVEC/
0.1% FBS. (iii) HUVEC/EGNP-1/0.1% FBS/EGF. (iv) HU-
VEC/EGNP-1/0.03pM GIPCsiRNA/0.1% FBS/EGF. (v) HU-
VEC/EGNP-1/0.3pM GIPCsiRNA/0.1% FBS/EGF. (vi) HU-
VEC/EGNP-1/3pM GIPCsiRNA/0.1% FBS/EGF. (vii)
HUVEC/EGNP-1/3pM control siRNA/0.1% FBS/EGF. b.
Determination of the quantity of apoptotic EC nuclei in zebrafish
(n.30). Fluorescent image of embryos injected with indicated
morpholinos and mRNA, then subjected to the antibody stain with
anti-GFP antibody and TUNEL assay to detect apoptosis. Insets
show a magnification of apoptotic foci in the vessel. The arrows
indicate apoptotic EC. i. Control; ii. zGIPC MOs (1.5 ng); iii.
zGIPC MO (4.5 ng); iv. zGIPC MO (4.5 ng)+hGIPC mRNA
(0.1 ng); v. zGIPC (4.5 ng)+hGIPC mRNA (0.3 ng); vi. zGIPC MO
(4.5 ng)+hGIPCDPDZ mRNA (0.1 ng); vii. zGIPC MO
(4.5 ng)+hGIPCDPDZ mRNA (0.3 ng). c. Determination of the
quantity of vessel defects (n.30) in embryos as in b. *p,0.001,
**p,0.005, ***p,0.01, ****p,0.05 in a Student’s t test.
Found at: doi:10.1371/journal.pone.0001161.s002 (1.82 MB TIF)
Figure S3 PI-3K/Akt is Involved in NRP-1-mediated HUVEC
survival. a. PI3K is involved in NRP-1-mediated EC survival
signaling. Apoptosis assay was performed in HUVEC transfected
with EGNP-1 or co-transfected with EGNP-1 with p85(DN) and
stimulated with or without 10 ng/ml EGF for 48 hours, and then
treated with LY294002 for 39 minutes, accordingly. (i) HUVEC/
5%FBS. (ii) HUVEC/0.1%FBS. (iii) HUVEC/EGNP-1/EGF. (iv)
HUVEC/LacZ/EGF. (v) HUVEC/EGNP-1+ 25mMLy294002/
EGF. (vi) HUVEC/EGNP-1, p85(DN)/EGF. (vii) HUVEC/
EGNP-1, p110CAAX/EGF. b. Akt is involved in PI3K-mediated
NRP-1 survival signaling in EC. Apoptosis assays were performed
in HUVEC transfected with EGNP-1 or cotransfected EGNP-1
with Akt(DN) or Akt(Active) and stimulated with or without
NRP-1 and p53/Caspases Axis
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0.1%FBS. (iii) HUVEC/EGNP-1/0.1%FBS/EGF. (iv) HUVEC/
EGNP-1, LacZ/0.1%FBS/EGF. (v) HUVEC/EGNP-1,
Akt(DN)/0.1%FBS/EGF. (vi) HUVEC/EGNP-1, Akt(Active)/
0.1% FBS/EGF.
Found at: doi:10.1371/journal.pone.0001161.s003 (4.46 MB TIF)
Figure S4 p53 inactivation in NRP-1-mediated EC survival. a.
Determination of the quantity of apoptotic EC nuclei in zebrafish
embryos (n.30). Fluorescent image of embryos injected with
indicated morpholinos and subjected to the antibody stain with
anti-GFP antibody and TUNEL assay to detect apoptosis. i.
Control; ii. zNRP-1a/1b MOs (4.5 ng+4.5 ng); iii. zNRP- 1a/1b
MOs (4.5 ng+4.5 ng)+zp53 MO (4.5 ng); vi. zNRP-1a/1b MOs
(4.5 ng+4.5 ng)+zp53 MO (9.0 ng); v. zMdm2 MO (4.5 ng); vi.
zMdm2 MO (4.5 ng)+zp53 MO (4.5 ng); vii. zMdm2 MO
(4.5 ng)+zp53 MO (9.0 ng). b. Determination of the quantity of
vessel defects (n.30) in embryos as in b. *p,0.001, **p,0.005,
***p,0.01, ****p,0.05 in a Student’s t test.
Found at: doi:10.1371/journal.pone.0001161.s004 (0.17 MB TIF)
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